Phase 1 Study to Assess Safety and Efficacy of ANG003

Prior treatment

• CF pulmonary exacerbation within 30 days prior to the Baseline SACT Period (Visit 2).

Other illness

• Subjects with diabetes mellitus who are unable to refrain from short-acting and rapid-acting insulin on Days 1 and 5 for a daily total of 6 hours.

Other

• Involuntary loss of ≥10% of usual body weight within last 6 months or involuntary loss of \>5% of body weight within 1 month.
• Requires use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration.
• Subjects who cannot discontinue omega-3 supplements \>500 mg of DHA and EPA daily.
• Subjects unable to tolerate missing a dose of PERT.

• Male and female subjects 18 years of age or older.
• Confirmed diagnosis of CF defined as: a) CF signs and symptoms AND b) Two CF-causing mutations on genetic testing or sweat chloride \>60 mEq/L.
• Documented history of fecal elastase \<100 µg/g stool.
• EPI clinically controlled with minimal clinical symptoms and on a stable dose of PERT for 90 days before screening as determined by the Investigator.
• Adequate nutritional status measured by body mass index ≥20kg/m2 for adult subjects.